2021
DOI: 10.1101/2021.02.01.429100
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Refining the Identity and Role of Kv4 Channels in Mouse Substantia Nigra Dopaminergic Neurons

Abstract: Substantia nigra pars compacta (SNc) dopaminergic (DA) neurons display a peculiar electrical phenotype characterized in vitro by a spontaneous tonic regular activity (pacemaking activity), a broad action potential and a biphasic post-inhibitory response. Several studies in rodents have underlined the central role played by the transient A-type current (IA) in the control of pacemaking activity and post-inhibitory rebound properties, thereby influencing both DA release and the physiological response of SNc neur… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2
1

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 55 publications
0
1
0
Order By: Relevance
“…Those studies, and ours, did not test for effects of saturating concentrations of 4AP (e.g., Serôdio et al, 1996 ). Also, we know of no K + channel antagonist that is specific for the Kv4.3 isoform that we focus on below ( Sanguinetti et al, 1997 ; Sergeant et al, 2005 ; Diochot et al, 2009 ; Jeong et al, 2011 , 2012 ; Fischer et al, 2013 ; Maffie et al, 2013 ; Kimm and Bean, 2014 ; see also Grissmer et al, 1994 ; Mlayah-Bellalouna et al, 2014 ; Haddjeri-Hopkins et al, 2021 ) and therefore did not test for effects of antagonists beside 4AP (e.g., heteropodatoxin, flecainide, phrixotoxin, dapoxetine, duloxetine, rosiglitazone, ajmaline, AmmTX3, SNX-482).…”
Section: Resultsmentioning
confidence: 99%
“…Those studies, and ours, did not test for effects of saturating concentrations of 4AP (e.g., Serôdio et al, 1996 ). Also, we know of no K + channel antagonist that is specific for the Kv4.3 isoform that we focus on below ( Sanguinetti et al, 1997 ; Sergeant et al, 2005 ; Diochot et al, 2009 ; Jeong et al, 2011 , 2012 ; Fischer et al, 2013 ; Maffie et al, 2013 ; Kimm and Bean, 2014 ; see also Grissmer et al, 1994 ; Mlayah-Bellalouna et al, 2014 ; Haddjeri-Hopkins et al, 2021 ) and therefore did not test for effects of antagonists beside 4AP (e.g., heteropodatoxin, flecainide, phrixotoxin, dapoxetine, duloxetine, rosiglitazone, ajmaline, AmmTX3, SNX-482).…”
Section: Resultsmentioning
confidence: 99%